---
document_datetime: 2025-12-02 05:07:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/spevigo.html
document_name: spevigo.html
version: success
processing_time: 0.1192176
conversion_datetime: 2025-12-29 20:05:53.904286
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Spevigo

[RSS](/en/individual-human-medicine.xml/67638)

##### Authorised

This medicine is authorised for use in the European Union

spesolimab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Spevigo](#news-on)
- [More information on Spevigo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Spevigo is a medicine that acts on the immune system. It is used in adults and adolescents from 12 years of age to prevent and treat flare-ups (recurrence or worsening) of generalised pustular psoriasis, an inflammatory skin disease causing pustules (pus-filled lesions) to appear over large areas of skin.

Spevigo contains the active substance spesolimab.

Expand section

Collapse section

## How is Spevigo used?

Spevigo can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in managing patients with inflammatory skin diseases.

When used to prevent flare-ups, Spevigo is injected under the skin of the upper thigh or abdomen (belly) every four weeks, using a pre-filled syringe. Patients and carers can inject the medicines themselves after receiving appropriate training.

When used to treat flare-ups, the medicine is given once as an infusion (drip) into a vein over 90 minutes; a second dose can be given one week later if symptoms are still present.

For more information about using Spevigo, see the package leaflet or contact your doctor or pharmacist.

## How does Spevigo work?

The active substance in Spevigo, spesolimab, is a monoclonal antibody (a type of protein) that binds to and blocks the receptor (target) for a protein involved in inflammation called interleukin-36 (IL-36). By preventing IL-36 from attaching to its receptor, Spevigo reduces inflammation and improves the symptoms of generalised pustular psoriasis.

## What benefits of Spevigo have been shown in studies?

A main study involving 53 adults with generalised pustular psoriasis flare-ups of moderate to severe intensity showed that Spevigo was more effective than placebo (a dummy treatment) at improving symptoms of the disease. After one week, 54% (19 out of 35 patients) of those who received a single dose of Spevigo had no visible pustules compared with 6% (1 out of 18 patients) of those who were given placebo, as measured using the GPPGA pustulation subscore (a measure of the severity of the pustules).

Another main study involved 123 adults and adolescents with a history of generalised pustular psoriasis. Over 48 weeks of treatment, 10% (3 out of 30) of patients using Spevigo had one or more flare-ups, compared with 52% (16 out of 31) of patients on placebo.

## What are the risks associated with Spevigo?

For the full list of side effects and restrictions with Spevigo, see the package leaflet.

The most common side effects with Spevigo (which may affect more than 1 in 10 people) are infections.

Spevigo must not be given to patients who have an active infection that the doctor considers important.

## Why is Spevigo authorised in the EU?

The severity of generalised pustular psoriasis flare-ups varies but can lead to organ failure and sepsis (blood poisoning). The disease is therefore a considerable burden on patients' lives. At the time of approval, there were no approved treatments for flare-ups of generalised pustular psoriasis and most therapies used in clinical practice had limited data on safety and efficacy.

Spevigo has been shown to be effective at preventing flare-ups and at clearing pustules within one week following a flare-up. Although safety data are limited, the safety profile is considered manageable.

Spevigo has been given 'conditional authorisation'. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The European Medicines Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company must provide further data on Spevigo. It must submit data from a study of the medicine in the treatment of recurrent flare-ups in patients with generalised pustular psoriasis to confirm its safety and effectiveness. Every year, the Agency will review any new information that becomes available.

## What information is still awaited for Spevigo?

Since Spevigo has been given conditional authorisation, the company that markets the medicine will provide data from a study of the medicine in the treatment of recurrent flare-ups in patients with generalised pustular psoriasis to confirm its safety and effectiveness.

## What measures are being taken to ensure the safe and effective use of Spevigo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Spevigo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Spevigo are continuously monitored. Suspected side effects reported with Spevigo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Spevigo

Spevigo received a conditional marketing authorisation valid throughout the EU on 09 December 2022.

Spevigo : EPAR - Medicine Overview

Reference Number: EMA/361482/2024

English (EN) (112.25 KB - PDF)

**First published:** 08/02/2023

**Last updated:** 10/10/2024

[View](/en/documents/overview/spevigo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-417)

български (BG) (138.4 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/bg/documents/overview/spevigo-epar-medicine-overview_bg.pdf)

español (ES) (111.54 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/es/documents/overview/spevigo-epar-medicine-overview_es.pdf)

čeština (CS) (135.3 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/cs/documents/overview/spevigo-epar-medicine-overview_cs.pdf)

dansk (DA) (110.02 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/da/documents/overview/spevigo-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.03 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/de/documents/overview/spevigo-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.91 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/et/documents/overview/spevigo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (136.16 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/el/documents/overview/spevigo-epar-medicine-overview_el.pdf)

français (FR) (112.82 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/fr/documents/overview/spevigo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133.97 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/hr/documents/overview/spevigo-epar-medicine-overview_hr.pdf)

italiano (IT) (110.71 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/it/documents/overview/spevigo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (141.56 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/lv/documents/overview/spevigo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.59 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/lt/documents/overview/spevigo-epar-medicine-overview_lt.pdf)

magyar (HU) (134.66 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/hu/documents/overview/spevigo-epar-medicine-overview_hu.pdf)

Malti (MT) (136.26 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/mt/documents/overview/spevigo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.39 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/nl/documents/overview/spevigo-epar-medicine-overview_nl.pdf)

polski (PL) (137.11 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/pl/documents/overview/spevigo-epar-medicine-overview_pl.pdf)

português (PT) (112.79 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/pt/documents/overview/spevigo-epar-medicine-overview_pt.pdf)

română (RO) (132.86 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/ro/documents/overview/spevigo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.42 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/sk/documents/overview/spevigo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (132.36 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/sl/documents/overview/spevigo-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.17 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/fi/documents/overview/spevigo-epar-medicine-overview_fi.pdf)

svenska (SV) (109.44 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

10/10/2024

[View](/sv/documents/overview/spevigo-epar-medicine-overview_sv.pdf)

Spevigo : EPAR - Risk Management Plan

English (EN) (2.44 MB - PDF)

**First published:** 08/02/2023

**Last updated:** 21/08/2025

[View](/en/documents/rmp/spevigo-epar-risk-management-plan_en.pdf)

## Product information

Spevigo : EPAR - Product Information

English (EN) (1.71 MB - PDF)

**First published:** 08/02/2023

**Last updated:** 19/09/2025

[View](/en/documents/product-information/spevigo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-691)

български (BG) (1.82 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/bg/documents/product-information/spevigo-epar-product-information_bg.pdf)

español (ES) (1.8 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/es/documents/product-information/spevigo-epar-product-information_es.pdf)

čeština (CS) (1.81 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/cs/documents/product-information/spevigo-epar-product-information_cs.pdf)

dansk (DA) (1.56 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/da/documents/product-information/spevigo-epar-product-information_da.pdf)

Deutsch (DE) (1.8 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/de/documents/product-information/spevigo-epar-product-information_de.pdf)

eesti keel (ET) (1.66 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/et/documents/product-information/spevigo-epar-product-information_et.pdf)

ελληνικά (EL) (1.91 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/el/documents/product-information/spevigo-epar-product-information_el.pdf)

français (FR) (1.76 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/fr/documents/product-information/spevigo-epar-product-information_fr.pdf)

hrvatski (HR) (1.79 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/hr/documents/product-information/spevigo-epar-product-information_hr.pdf)

íslenska (IS) (1.57 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/is/documents/product-information/spevigo-epar-product-information_is.pdf)

italiano (IT) (1.81 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/it/documents/product-information/spevigo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.73 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/lv/documents/product-information/spevigo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.79 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/lt/documents/product-information/spevigo-epar-product-information_lt.pdf)

magyar (HU) (1.77 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/hu/documents/product-information/spevigo-epar-product-information_hu.pdf)

Malti (MT) (1.74 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/mt/documents/product-information/spevigo-epar-product-information_mt.pdf)

Nederlands (NL) (1.71 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/nl/documents/product-information/spevigo-epar-product-information_nl.pdf)

norsk (NO) (1.56 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/no/documents/product-information/spevigo-epar-product-information_no.pdf)

polski (PL) (1.72 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/pl/documents/product-information/spevigo-epar-product-information_pl.pdf)

português (PT) (1.73 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/pt/documents/product-information/spevigo-epar-product-information_pt.pdf)

română (RO) (1.76 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/ro/documents/product-information/spevigo-epar-product-information_ro.pdf)

slovenčina (SK) (1.84 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/sk/documents/product-information/spevigo-epar-product-information_sk.pdf)

slovenščina (SL) (1.82 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/sl/documents/product-information/spevigo-epar-product-information_sl.pdf)

Suomi (FI) (1.66 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/fi/documents/product-information/spevigo-epar-product-information_fi.pdf)

svenska (SV) (1.69 MB - PDF)

**First published:**

08/02/2023

**Last updated:**

19/09/2025

[View](/sv/documents/product-information/spevigo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** X/0011 14/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Spevigo : EPAR - All authorised presentations

English (EN) (47.88 KB - PDF)

**First published:** 08/02/2023

**Last updated:** 21/08/2025

[View](/en/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-333)

български (BG) (55.13 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/bg/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.81 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/es/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.5 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/cs/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.34 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/da/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.42 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/de/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.48 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/et/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.99 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/el/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_el.pdf)

français (FR) (48.16 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/fr/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.93 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/hr/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.68 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/is/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.37 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/it/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.42 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/lv/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.39 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/lt/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.96 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/hu/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.88 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/mt/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.94 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/nl/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.43 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/no/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_no.pdf)

polski (PL) (53.09 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/pl/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.63 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/pt/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.66 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/ro/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.54 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/sk/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (47.35 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/sl/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.62 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/fi/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.81 KB - PDF)

**First published:**

08/02/2023

**Last updated:**

21/08/2025

[View](/sv/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Spevigo Active substance spesolimab International non-proprietary name (INN) or common name spesolimab Therapeutic area (MeSH) Psoriasis Anatomical therapeutic chemical (ATC) code L04AC22

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age.

Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.

## Authorisation details

EMA product number EMEA/H/C/005874

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173

Opinion adopted 13/10/2022 Marketing authorisation issued 09/12/2022 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Spevigo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.87 KB - PDF)

**First published:** 16/06/2025

[View](/en/documents/procedural-steps-after/spevigo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Spevigo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (157.89 KB - PDF)

**First published:** 10/10/2024

**Last updated:** 21/08/2025

[View](/en/documents/procedural-steps-after/spevigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Spevigo-H-C-005874-X-0011 : EPAR - Assessment report

Adopted

Reference Number: EMA/222233/2025

English (EN) (1.18 MB - PDF)

**First published:** 21/08/2025

[View](/en/documents/variation-report/spevigo-h-c-005874-x-0011-epar-assessment-report_en.pdf)

Spevigo-H-C-005874-X-0006-G : EPAR - Assessment report

Adopted

Reference Number: EMA/372955/2024

English (EN) (6.61 MB - PDF)

**First published:** 10/10/2024

[View](/en/documents/variation-report/spevigo-h-c-005874-x-0006-g-epar-assessment-report_en.pdf)

Spevigo : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

English (EN) (113.17 KB - PDF)

**First published:** 10/10/2024

[View](/en/documents/pip-compliance/spevigo-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

CHMP post-authorisation summary of opinion for Spevigo (X-06-G)

Adopted

Reference Number: EMA/331897/2024

English (EN) (121.99 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-spevigo-x-06-g_en.pdf)

## Initial marketing authorisation documents

Spevigo : EPAR - Public assessment report

Adopted

Reference Number: EMA/50357/2023

English (EN) (4.7 MB - PDF)

**First published:** 08/02/2023

[View](/en/documents/assessment-report/spevigo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Spevigo

Adopted

Reference Number: EMA/CHMP/804058/2022

English (EN) (98.55 KB - PDF)

**First published:** 14/10/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-spevigo_en.pdf)

#### News on Spevigo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

#### More information on Spevigo

- [EMEA-002475-PIP03-22-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002475-pip03-22-m01)
- [EMEA-002475-PIP04-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002475-pip04-23)
- [A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasis - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000278)
- [Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms) - post-authorisation study](https://catalogues.ema.europa.eu/study/49954)

**This page was last updated on** 21/08/2025

## Share this page

[Back to top](#main-content)